ArticleCancers2023

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.

Davide Ciardiello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.